[ad_1]
A The coronavirus vaccine developed by AstraZeneca and the University of Oxford can be up to 90 percent effective in preventing people from contracting Covid-19, preliminary data shows.
The overall results of phase three of the trial show that the vaccine is 70.4% effective.
But when given at a half dose and then a full dose, the vaccine can be up to 90 percent effective, the scientists said.
When given in two full doses, it is 62 percent effective.
The study, which involved more than 24,000 volunteers, showed that there were no serious cases among those who received the vaccine, including hospitalizations, the researchers said.
Matt Hancock, the Health Secretary, said the UK has orders for 100 million doses of the vaccine and it is expected to be rolled out in the new year.
Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: “These findings show that we have an effective vaccine that will save many lives. Interestingly, we have found that one of our dosing regimens can be around 90 percent effective, and if this dosing regimen is used, more people could be vaccinated with the planned vaccine supply.
“Today’s announcement is only made possible by the many volunteers in our trial and the talented and hardworking team of researchers from around the world.”
Unlike the Pfizer vaccine, the Oxford vaccine can be stored at 2-8 ° C, which makes distribution and storage easier.
[ad_2]
